Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combined Nabpaclitaxel pressurized intraPeritoneal aerosol chemotherapy with systemic Nabpaclitaxel-Gemcitabine chemotherapy for pancreatic cancer peritoneal metastases: protocol of single-arm, open-label, phase II trial (Nab-PIPAC trial).
Di Giorgio A, Ferracci F, Bagalà C, Carbone C, Salvatore L, Strippoli A, Attalla El Halabieh M, Abatini C, Alfieri S, Pacelli F, Tortora G. Di Giorgio A, et al. Among authors: bagala c. Pleura Peritoneum. 2024 Nov 6;9(3):121-129. doi: 10.1515/pp-2024-0010. eCollection 2024 Sep. Pleura Peritoneum. 2024. PMID: 39544430 Free PMC article.
Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis.
Mastrantoni L, Chiaravalli M, Spring A, Beccia V, Di Bello A, Bagalà C, Bensi M, Barone D, Trovato G, Caira G, Giordano G, Bria E, Tortora G, Salvatore L. Mastrantoni L, et al. Among authors: bagala c. Lancet Oncol. 2024 Dec;25(12):1655-1665. doi: 10.1016/S1470-2045(24)00511-4. Epub 2024 Nov 11. Lancet Oncol. 2024. PMID: 39542008
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.
Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, Lopez CD, Bekaii-Saab T, Ko AH, Santoro A, Park JO, Noel MS, Frassineti GL, Shan YS, Dean A, Riess H, Van Cutsem E, Berlin J, Philip P, Moore M, Goldstein D, Tabernero J, Li M, Ferrara S, Le Bruchec Y, Zhang G, Lu B, Biankin AV, Reni M; APACT Investigators. Tempero MA, et al. J Clin Oncol. 2023 Apr 10;41(11):2007-2019. doi: 10.1200/JCO.22.01134. Epub 2022 Dec 15. J Clin Oncol. 2023. PMID: 36521097 Free PMC article. Clinical Trial.
Role of Chemoradiation in the Adjuvant Treatment of Radically Resected Pancreatic Cancer Patients: A Mono-Institutional Retrospective Analysis.
Mattiucci GC, Salvatore L, D'Aviero A, Bagalà C, Bensi M, Castronovo FM, Cellini F, De Franco P, Di Stefano B, Macchia G, Masiello V, Menghi R, Quero G, Reina S, Morganti AG, Alfieri S, Tortora G, Valentini V. Mattiucci GC, et al. Among authors: bagala c. Oncol Res Treat. 2022;45(10):588-597. doi: 10.1159/000525945. Epub 2022 Jul 26. Oncol Res Treat. 2022. PMID: 35882183
The impact of the multidisciplinary tumor board (MDTB) on the management of pancreatic diseases in a tertiary referral center.
Quero G, Salvatore L, Fiorillo C, Bagalà C, Menghi R, Maria B, Cina C, Laterza V, Di Stefano B, Maratta MG, Ribelli M, Galiandro F, Mattiucci GC, Brizi MG, Genco E, D'Aversa F, Zileri L, Attili F, Larghi A, Perri V, Inzani F, Gasbarrini A, Valentini V, Costamagna G, Manfredi R, Tortora G, Alfieri S. Quero G, et al. Among authors: bagala c. ESMO Open. 2021 Feb;6(1):100010. doi: 10.1016/j.esmoop.2020.100010. Epub 2020 Dec 14. ESMO Open. 2021. PMID: 33399076 Free PMC article.
Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma.
Di Giorgio A, Sgarbura O, Rotolo S, Schena CA, Bagalà C, Inzani F, Russo A, Chiantera V, Pacelli F. Di Giorgio A, et al. Among authors: bagala c. Ther Adv Med Oncol. 2020 Jul 24;12:1758835920940887. doi: 10.1177/1758835920940887. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32782488 Free PMC article.
RUNX3 as a Potential Predictor of Metastasis in Human Pancreatic Cancer.
Rossi E, Bagalà C, Inzani F, Leoncini E, Brunelli C, Lanza P, Basso M, Mattiucci GC, Cassano A, Rindi G, Barone C, Schinzari G. Rossi E, et al. Among authors: bagala c. In Vivo. 2017 Sep-Oct;31(5):833-840. doi: 10.21873/invivo.11136. In Vivo. 2017. PMID: 28882948 Free PMC article.
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
Orlandi A, Calegari MA, Martini M, Cocomazzi A, Bagalà C, Indellicati G, Zurlo V, Basso M, Cassano A, Larocca LM, Barone C. Orlandi A, et al. Among authors: bagala c. Clin Transl Oncol. 2016 Oct;18(10):988-95. doi: 10.1007/s12094-015-1471-z. Epub 2016 Jan 7. Clin Transl Oncol. 2016. PMID: 26742940
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer.
Aglietta M, Barone C, Sawyer MB, Moore MJ, Miller WH Jr, Bagalà C, Colombi F, Cagnazzo C, Gioeni L, Wang E, Huang B, Fly KD, Leone F. Aglietta M, et al. Among authors: bagala c. Ann Oncol. 2014 Sep;25(9):1750-1755. doi: 10.1093/annonc/mdu205. Epub 2014 Jun 6. Ann Oncol. 2014. PMID: 24907635 Free article. Clinical Trial.
27 results